International Needle-free Vaccination Alliance (INVax) (2009-2012)
Abstract
INVax will bring together world leaders to develop a new vaccine technology based on a micro-nanoprojection array (the Nanopatch) as a commercially-viable vaccine delivery system. Nanopatches when combined with vaccines are designed to induce better immunity more cheaply, than vaccines currently delivered with the needle and syringe. To achieve this, the expertise of Queensland-based investigators will be partnered by the Seattle Biomedical Research Institute (SBRI), the Program for Appropriate Technology in Health (PATH) and the World Health Organisation (WHO) in a focussed project to develop the Nanopatch in three key vaccination areas. Success with Nanopatches - being user friendly and cheap to manufacture and distribute - will have clear utility worldwide.
